X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA TORRENT PHARMA NATCO PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 16.0 44.0 36.3% View Chart
P/BV x 17.2 6.2 276.7% View Chart
Dividend Yield % 0.7 0.8 80.7%  

Financials

 NATCO PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
TORRENT PHARMA
Mar-18
NATCO PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs8771,550 56.6%   
Low Rs4241,144 37.0%   
Sales per share (Unadj.) Rs223.4354.7 63.0%  
Earnings per share (Unadj.) Rs31.140.1 77.5%  
Cash flow per share (Unadj.) Rs40.364.2 62.7%  
Dividends per share (Unadj.) Rs5.0014.00 35.7%  
Dividend yield (eoy) %0.81.0 74.0%  
Book value per share (Unadj.) Rs219.5273.1 80.4%  
Shares outstanding (eoy) m33.07169.22 19.5%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.8 76.6%   
Avg P/E ratio x20.933.6 62.3%  
P/CF ratio (eoy) x16.121.0 77.0%  
Price / Book Value ratio x3.04.9 60.1%  
Dividend payout %16.134.9 46.1%   
Avg Mkt Cap Rs m21,504227,897 9.4%   
No. of employees `000NA14.7 0.0%   
Total wages/salary Rs m1,12811,353 9.9%   
Avg. sales/employee Rs ThNM4,083.0-  
Avg. wages/employee Rs ThNM772.3-  
Avg. net profit/employee Rs ThNM461.3-  
INCOME DATA
Net Sales Rs m7,38960,021 12.3%  
Other income Rs m1672,988 5.6%   
Total revenues Rs m7,55663,009 12.0%   
Gross profit Rs m1,79313,493 13.3%  
Depreciation Rs m3044,086 7.4%   
Interest Rs m3663,085 11.9%   
Profit before tax Rs m1,2909,310 13.9%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3092,529 12.2%   
Profit after tax Rs m1,0276,781 15.2%  
Gross profit margin %24.322.5 108.0%  
Effective tax rate %23.927.2 88.1%   
Net profit margin %13.911.3 123.1%  
BALANCE SHEET DATA
Current assets Rs m3,68152,623 7.0%   
Current liabilities Rs m3,12352,022 6.0%   
Net working cap to sales %7.61.0 754.3%  
Current ratio x1.21.0 116.5%  
Inventory Days Days89120 74.8%  
Debtors Days Days5976 77.0%  
Net fixed assets Rs m7,68585,016 9.0%   
Share capital Rs m331846 39.1%   
"Free" reserves Rs m6,67045,376 14.7%   
Net worth Rs m7,25946,222 15.7%   
Long term debt Rs m95541,115 2.3%   
Total assets Rs m11,957142,432 8.4%  
Interest coverage x4.54.0 112.5%   
Debt to equity ratio x0.10.9 14.8%  
Sales to assets ratio x0.60.4 146.6%   
Return on assets %11.76.9 168.3%  
Return on equity %14.214.7 96.5%  
Return on capital %20.714.2 146.0%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,44514,580 23.6%   
Fx outflow Rs m7033,600 19.5%   
Net fx Rs m2,74310,980 25.0%   
CASH FLOW
From Operations Rs m1,4408,942 16.1%  
From Investments Rs m-1,089-47,070 2.3%  
From Financial Activity Rs m-35334,174 -1.0%  
Net Cashflow Rs m-1-3,655 0.0%  

Share Holding

Indian Promoters % 52.0 71.5 72.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 7.0 111.7%  
FIIs % 16.6 12.6 132.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 8.8 295.5%  
Shareholders   25,395 26,511 95.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   NOVARTIS  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  ALKEM LABORATORIES  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Depreciating Rupee; IPO Buzz and Top Cues in Focus Today(Pre-Open)

Indian share markets ended lower yesterday with banking stocks and metal stocks leading the losses. At the closing bell, the BSE Sensex ended down by 188 points (0.5%).

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 16, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - AJANTA PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS